Hyperthermia treatment technology developer Pyrexar Medical has implemented its BSD-2000 3D/MR image-guided hyperthermia cancer treatment system at Ludwig Maximilians University in Munich, Germany.
The institution has used hyperthermia to treat over 15,000 patients, many of them with soft-tissue sarcoma tumors, according to Pyrexar. Ludwig Maximilians was part of a phase III clinical study that showed the long-term survival benefits of adding hyperthermia to chemotherapy, Pyrexar said. In addition, the university is involved in the Hyperthermia European Adjuvant Trial (HEAT), a randomized dual-arm study using chemotherapy and hyperthermia to treat pancreatic cancer.
BSD-2000 3D/MR, which fits most 1.5-tesla MR scanners in the market that have a magnet bore 60 cm or greater, uses MRI to visualize temperature in the treatment area, Pyrexar said. Operators can then use this 3D information to adjust the heating zone in the body, according to the vendor.